Greenwich LifeSciences, Inc.
GLSI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,522 | $3,508 | $2,601 | $6,158 |
| G&A Expenses | $0 | $538 | $681 | $0 |
| SG&A Expenses | $653 | $538 | $681 | $1,926 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,175 | $4,046 | $3,282 | $8,083 |
| Operating Income | -$4,175 | -$4,046 | -$3,282 | -$8,084 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $23 | $21 | $24 | $44 |
| Pre-Tax Income | -$4,152 | -$4,025 | -$3,258 | -$8,040 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,152 | -$4,025 | -$3,258 | -$8,040 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -0.3 | -0.25 | -0.61 |
| % Growth | 0% | -20% | 59% | – |
| EPS Diluted | -0.3 | -0.3 | -0.25 | -0.61 |
| Weighted Avg Shares Out | 13,641 | 13,371 | 13,172 | 13,153 |
| Weighted Avg Shares Out Dil | 13,641 | 13,371 | 13,172 | 13,153 |
| Supplemental Information | – | – | – | – |
| Interest Income | $23 | $21 | $24 | $44 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$4,152 | -$4,045 | -$3,281 | -$8,039 |
| % Margin | – | – | – | – |